<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01756508</url>
  </required_header>
  <id_info>
    <org_study_id>Eculizumab for reperfusion</org_study_id>
    <nct_id>NCT01756508</nct_id>
  </id_info>
  <brief_title>Eculizumab for Prevention and Treatment of Kidney Graft Reperfusion Injury</brief_title>
  <official_title>Study of Eculizumab for Prevention and Treatment Reperfusion Injury in Kidney Transplantation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Russian Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Russian Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study of eculizumab ability to correct the reperfusion injury of the kidney allograft.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Based on experimental data and supportive observations in humans associating complement gene
      upregulation with ischemic reperfusion injury, it is hypothesized that C5 cleavage is a key
      step in the pathogenesis of ischemic reperfusion injury following transplantation. It was
      further hypothesized that eculizumab, antibody that blocks C5 cleavage in humans will be an
      effective prophylactic agent to prevent ischemic reperfusion injury in high risk recipients.
      For testing this hypothesis, this study is a pilot prospective study to test the efficacy of
      eculizumab in preventing the development of reperfusion injury and contribute graft survival.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>speed of the graft warming</measure>
    <time_frame>at the time of engraftment</time_frame>
    <description>The speed of the graft surface warming in the range 15-20Â°C is accessed on the the infrared video record, taken during graft reperfusion by Nec Thermo Tracer.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>initial graft function</measure>
    <time_frame>first week after Tx</time_frame>
    <description>initial graft function will be accessed daily during the first week post Tx and measured as follows:
the rate of serum creatinine decrease expressed as percent per day, where 100% will be the creatinine on the day before;
intragraft blood flow by Doppler indexes (acceleration, resistance) and blood flow velocity on the three levels - main, interlobar and arcuate arteries;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>graft morphology changes</measure>
    <time_frame>one year after transplantation</time_frame>
    <description>Protocol biopsy will be obtained at one month and one year. Progression of allograft nephropathy will be compared between groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>One-year graft and patient survival, as well as rejection and infection rates will be calculated</measure>
    <time_frame>one year after Tx</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>End-Stage Renal Disease</condition>
  <condition>Kidney Failure</condition>
  <condition>Graft Reperfusion Injury</condition>
  <arm_group>
    <arm_group_label>eculizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eculizumab 1200 mg/m2 will be administered once, 1 hour before graft reperfusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention will be applied instead eculizumab infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>eculizumab</intervention_name>
    <description>Eculizumab 1200 mg/m2 will be administered once, 1 hour before graft reperfusion</description>
    <arm_group_label>eculizumab</arm_group_label>
    <other_name>Soliris</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. age 1-80

          2. weight - &gt;6 kg

          3. male or female

          4. recipient of first kidney graft either from standard criteria deceased or live donor

          5. end stage renal disease or congenital nephrotic syndrome -

        Exclusion Criteria:

          1. Blood group (ABO) incompatible transplantation

          2. presence of donor-specific anti-human leukocyte antigen (HLA) antibodies

          3. multiorgan transplantation

          4. previous transplant

          5. patients infected with HIV, hepatitis C virus (HCV) or hepatitis B virus (HBV)

          6. patients with haemolytic-uraemic syndrome (HUS) -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael M Kaabak, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Russian Scientific Center of Surgery</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael M Kaabak, professor</last_name>
    <phone>8-499-248-13-44</phone>
    <email>kaabak@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Victor A Goryainov, doctor</last_name>
    <phone>8-926-532-70-04</phone>
    <email>vik-kid@mail.ru</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Russian Scientfic Center of Surgery</name>
      <address>
        <city>Moscow</city>
        <zip>119992</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael M Kaabak, MD</last_name>
      <email>kaabak@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Victor A Goryainov</last_name>
      <phone>926- 532-7004</phone>
      <email>vik-kid@mail.ru</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <reference>
    <citation>de Vries DK, van der Pol P, van Anken GE, van Gijlswijk DJ, Damman J, Lindeman JH, Reinders ME, Schaapherder AF, Kooten Cv. Acute but transient release of terminal complement complex after reperfusion in clinical kidney transplantation. Transplantation. 2013 Mar 27;95(6):816-20. doi: 10.1097/TP.0b013e31827e31c9.</citation>
    <PMID>23348894</PMID>
  </reference>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2012</study_first_submitted>
  <study_first_submitted_qc>December 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 27, 2012</study_first_posted>
  <last_update_submitted>April 4, 2016</last_update_submitted>
  <last_update_submitted_qc>April 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Russian Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Michael Kaabak</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>eculizumab</keyword>
  <keyword>kidney transplantation</keyword>
  <keyword>reperfusion</keyword>
  <keyword>rejection</keyword>
  <keyword>infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Reperfusion Injury</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

